Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The association of anthracyclines (ANT) and paclitaxel (Tax) is one of the main treatments used in breast cancer. These treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. If exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. Among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. The PROTECT-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. The duration of the training program is 15 weeks with one session per week.
There will be two groups of patients after drawing lots using a process called randomization. The probability is one in two of being in the group participating in the training program, the other group following the standard treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Training group | Experimental | This group of patients will perform concentric cycling training program during the chemotherapy treatment. |
|
| Control group | No Intervention | This group of patients will benefit from standard care without additional training program. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Training sessions | Procedure | The training program will be performed during 15 weeks, with one session per week. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall exercise capacity | To investigate the superiority of a concentric pedaling training program during (neo)adjuvant chemotherapy versus the absence of a training program in patients with early breast cancer. The overall exercise capacity is assessed by the 6-minute walk test (TDM6) between the two groups. | At week 18 (the end of chemotherapy treatment) |
| Measure | Description | Time Frame |
|---|---|---|
| Physiological variables associated with exercise capacity - cardiorespiratory capacity | To examine the effects of the training program on VO2max. | At weeks 8. |
| Physiological variables associated with exercise capacity - cardiorespiratory capacity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Joris MALLARD, PhD | Contact | 368767419 | +33 | j.mallard@icans.eu |
| Name | Affiliation | Role |
|---|---|---|
| BENDER Laura, MD | Institut de cancérologie Strasbourg Europe | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpitaux civils de Colmar | Not yet recruiting | Colmar | 68024 | France |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
This is an interventional, randomized controlled, prospective, multicenter and adaptive study aimed at investigating the effect of a concentric pedaling training program carried out during (neo)adjuvant chemotherapy in addition to usual care.
Not provided
Not provided
Not provided
Not provided
To examine the effects of the training program on VO2max.
| At week 18 (the end of chemotherapy treatment) |
| Physiological variables associated with exercise capacity - muscle function | To examine the effects of the training program on maximal aerobic power determined as the lowest exercise intensity inducing a plateauing of O2 consumption during a maximum exercise test. | At weeks 8. |
| Physiological variables associated with exercise capacity - muscle function | To examine the effects of the training program on maximal aerobic power determined as the lowest exercise intensity inducing a plateauing of O2 consumption during a maximum exercise test. | At week 18 (the end of chemotherapy treatment) |
| Physiological variables associated with exercise capacity - body composition | To examine the effects of the training program on lean mass, fat mass, muscle mass assessed by bioimpedancemetry. | At weeks 8. |
| Physiological variables associated with exercise capacity - body composition | To examine the effects of the training program on lean mass, fat mass, muscle mass assessed by bioimpedancemetry. | At week 18 (the end of chemotherapy treatment) |
| Physiological variables associated with exercise capacity - muscle architecture | To examine the effects of the training program on muscle thickness assessed by ultrasonography. | At weeks 8. |
| Physiological variables associated with exercise capacity - muscle architecture | To examine the effects of the training program on fascicle length assessed by ultrasonography. | At weeks 8. |
| Physiological variables associated with exercise capacity - muscle architecture | To examine the effects of the training program on cross-sectional area assessed by ultrasonography. | At weeks 8. |
| Physiological variables associated with exercise capacity - muscle architecture | To examine the effects of the training program on muscle thickness assessed by ultrasonography. | At week 18 (the end of chemotherapy treatment) |
| Physiological variables associated with exercise capacity - muscle architecture | To examine the effects of the training program on fascicle length assessed by ultrasonography. | At week 18 (the end of chemotherapy treatment) |
| Physiological variables associated with exercise capacity - muscle architecture | To examine the effects of the training program on cross-sectional area assessed by ultrasonography. | At week 18 (the end of chemotherapy treatment) |
| Psychosocial variables associated with exercise capacity - quality of life | To examine the effects of the training program with the FACT-G questionnaire | At weeks 8. |
| Psychosocial variables associated with exercise capacity - quality of life | To examine the effects of the training program with the FACT-G questionnaire | At week 18 (the end of chemotherapy treatment) |
| Psychosocial variables associated with exercise capacity - fatigue | To examine the effects of the training program with the FACIT-F questionnaire | At weeks 8. |
| Psychosocial variables associated with exercise capacity - fatigue | To examine the effects of the training program with the FACIT-F questionnaire | At week 18 (the end of chemotherapy treatment) |
| Psychosocial variables associated with exercise capacity - appetite level | To examine the effects of the training program with the FAACT questionnaire | At weeks 8. |
| Psychosocial variables associated with exercise capacity - appetite level | To examine the effects of the training program with the FAACT questionnaire | At week 18 (the end of chemotherapy treatment) |
| Institut de cancérologie Strasbourg Europe | Recruiting | Strasbourg | 67033 | France |
|
| D017437 |
| Skin and Connective Tissue Diseases |